psychotropic medications

Lamotrigine and Menopausal Hormone Therapy: What Women Need to Know

Estrogen-containing menopausal hormone therapy (MHT) may lower blood levels of lamotrigine, potentially reducing its effectiveness in some women with bipolar disorder. What do we know about this interaction, and does the risk differ with oral, transdermal, or vaginal estrogen?

By |2026-09-01T11:32:34-04:00August 27th, 2026|Bipolar Disorder, Menopausal Symptoms, Menopause|Comments Off on Lamotrigine and Menopausal Hormone Therapy: What Women Need to Know

Essential Reads: Bupropion (Wellbutrin) and Risk for Major Malformations

Bupropion is commonly used to treat depression, and is also prescribed to support smoking cessation. Early data on bupropion-exposure during pregnancy raised concern for a possible increase in risk of malformations of the heart and large blood vessels in bupropion-exposed infants. Subsequent data from bupropion pregnancy registries has been reassuring, however, and do not demonstrate an overall increase in risk of cardiac defects following first trimester bupropion exposure. Although the overall risk of cardiac defects was not increased, the distribution of specific defects in these registries was unexpected in some ways. For example, the GlaxoSmithKline Bupropion Pregnancy Registry included two cases of coarctation of the aorta out of the 675 bupropion-exposed infants, compared to the rate of 6 cases per 10,000 births in the general population.

By |2021-10-27T20:42:23-04:00April 15th, 2021|Antidepressants, Essential Reads, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Essential Reads: Bupropion (Wellbutrin) and Risk for Major Malformations

Wellbutrin (Bupropion) Exposure and Risk of Cardiac Malformations

Bupropion is commonly used to treat depression, and is also prescribed to support smoking cessation. Early data on bupropion-exposure during pregnancy raised concern for a possible increase in risk of malformations of the heart and large blood vessels in bupropion-exposed infants. Subsequent data from bupropion pregnancy registries has been reassuring, however, and do not demonstrate an overall increase in risk of cardiac defects following first trimester bupropion exposure. Although the overall risk of cardiac defects was not increased, the distribution of specific defects in these registries was unexpected in some ways. For example, the GlaxoSmithKline Bupropion Pregnancy Registry included two cases of coarctation of the aorta out of the 675 bupropion-exposed infants, compared to the rate of 6 cases per 10,000 births in the general population.

By |2014-09-11T09:57:22-04:00September 11th, 2014|Antidepressants, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Wellbutrin (Bupropion) Exposure and Risk of Cardiac Malformations
Go to Top